血管表型中的表观遗传开关增加了抗瘤免疫力
bioRxiv : the preprint server for biology
|December 22, 2025
概括
向内皮细胞中的DNA甲基转移酶1可以减少瘤血管的生长,并增强抗瘤免疫力. 这种表观遗传策略改善了T细胞的透和对癌症免疫治疗的反应.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 异常的瘤血管阻碍了抗瘤免疫细胞的透,损害了免疫监测和免疫治疗反应.
- 内皮细胞 (ECs) 在调节瘤免疫微环境 (TIME) 中发挥着至关重要的作用.
研究的目的:
- 为了研究DNA甲基转移酶1 (DNMT1) 在内皮细胞 (ECs) 在调节瘤血管和抗瘤免疫中的作用.
- 探索向内皮DNMT1用于癌症免疫治疗的潜力.
主要方法:
- 在小鼠的EC中条件删除Dnmt1 (Dnmt1iECKO).
- 对瘤血管结构,免疫细胞透和T细胞共刺激分子表达的分析.
- 在体外EC培养物中用IFNy和TNFa处理.
- 评估免疫检查点阻塞 (ICB) 在Dnmt1iECKO小鼠中具有黑色素瘤肺转移的疗效.
主要成果:
- 向内皮DNMT1降低了血管生成和改变了瘤血管化,增加了免疫允许性血管.
- 在Dnmt1iECKO小鼠的瘤中观察到CD4+记忆T细胞和NK细胞的比例增加.
- 内皮DNMT1删除增强了对IFNy/TNFa和上调的T细胞共刺激分子的EC反应.
- 在患有肺转移的Dnmt1iECKO小鼠中,ICB治疗降低了瘤负担,有些人完全反应.
结论:
- 内皮DNMT1是血管介导的抗瘤免疫的关键调节者.
- 向内皮DNMT1在表观遗传上调节瘤血管结构,以增强免疫细胞透和免疫疗法的有效性.
- 这为结合血管系统的表观遗传调制与癌症免疫治疗提供了理由.
更多相关视频
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
9.2K
10:15Isolation and Culture Expansion of Tumor-specific Endothelial Cells
Published on: October 14, 2015
11.6K
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
